# 04_QA_REPORT.md

# Population Package QA Report

## Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0195 |
| PP ID | PP-0195 |
| Title | ESD / Endoscopic Submucosal Dissection |
| Version | 1.0.0 |
| QA Status | PASS — GOLD — READY FOR INTEGRATION |
| Decision Status | APPROVED / LOCKED |
| Production Status | GOLD |
| Source-First Status | PASS |
| Boundary Status | PASS |
| Knowledge Graph Status | PASS |
| Repository Readiness | PASS |

---

# 1. QA Scope

This QA Report evaluates the completed PP-0195 Gold package against:

1. The approved/locked PP-0195 Decision Batch.
2. CORE_WORKING_RULES v1.7.
3. FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.1.
4. Approved Discussion depth/format reference.
5. Gold artifact structure and depth requirements.
6. Project Source Materials.
7. Adjacent Population Package boundary requirements.
8. Patient-facing clinical safety requirements.
9. Evidence traceability requirements.
10. Knowledge Graph requirements.

---

# 2. Artifact Inventory

| Artifact | Required | Present | Result |
|---|---:|---:|---|
| 01_CKO.md | Yes | Yes | PASS |
| 02_KNOWLEDGE_PASSPORT.md | Yes | Yes | PASS |
| 03_PRIMARY_EVIDENCE_PACKAGE.md | Yes | Yes | PASS |
| 04_QA_REPORT.md | Yes | Yes | PASS |

### Artifact Structure

**Result: PASS**

Exactly four required Markdown artifacts are included.

---

# 3. Layer 1 — Content QA

## 3.1 Scope Integrity

| Criterion | Result | QA Note |
|---|---|---|
| Locked PP identity preserved | PASS | PP-0195 is consistently represented as ESD / Endoscopic Submucosal Dissection. |
| Locked title preserved | PASS | ESD is the package identity throughout all artifacts. |
| Atomic clinical question preserved | PASS | Package focuses on ESD as a modality for selected early gastric cancer. |
| No scope drift | PASS | No unrelated gastric-cancer treatment domain was absorbed. |
| No silent scope expansion | PASS | Technical ESD mechanics and detailed surgery remain excluded. |
| Approved decisions implemented | PASS | Decision Batch concepts are reflected in CKO, KP, EP and QA. |

---

## 3.2 Completeness of Core Content

| Core Topic | Result | QA Note |
|---|---|---|
| ESD definition | PASS | Explained in CKO and KP. |
| Therapeutic role | PASS | Explicitly described. |
| Specimen/staging role | PASS | Explicitly described. |
| Submucosal concept | PASS | Explained without becoming procedural. |
| En-bloc resection | PASS | Included as a major concept. |
| Early gastric cancer | PASS | Central population preserved. |
| Classic indications | PASS | Included. |
| Expanded indications | PASS | Included. |
| Tumor size | PASS | Included and qualified. |
| Histologic differentiation | PASS | Included conceptually. |
| Ulceration | PASS | Included. |
| Depth | PASS | Included as a central decision factor. |
| Superficial/deep submucosal invasion | PASS | Distinction preserved. |
| Nodal-risk rationale | PASS | Explicit. |
| LVI | PASS | Included. |
| Margins | PASS | Included. |
| EUS interface | PASS | Included at conceptual level. |
| Pathology | PASS | Included at interface level. |
| Curative assessment | PASS | Central concept. |
| Non-curative assessment | PASS | Central concept. |
| Additional treatment | PASS | Strategic downstream interface. |
| ESD versus EMR | PASS | Dedicated comparison. |
| ESD versus surgery | PASS | Strategic comparison. |
| Risks | PASS | Bleeding/perforation/high-level risk. |
| Expertise | PASS | Center/operator expertise emphasized. |
| East Asian context | PASS | Included. |
| Outcomes | PASS | Study-level evidence included. |
| Surveillance | PASS | Included conceptually. |
| Patient questions | PASS | Included. |
| Misconceptions | PASS | Dedicated section included. |

---

## 3.3 Scope Exclusion Integrity

| Excluded Topic | Result | QA Note |
|---|---|---|
| Detailed ESD technique | PASS | Explicitly excluded. |
| Device mechanics | PASS | Explicitly excluded. |
| Electrosurgical settings | PASS | Explicitly excluded. |
| Detailed complication treatment | PASS | Explicitly excluded. |
| Sedation/anesthesia | PASS | Explicitly excluded. |
| Detailed EUS | PASS | Explicitly excluded. |
| Full TNM methodology | PASS | Explicitly excluded. |
| Detailed pathology methodology | PASS | Explicitly excluded. |
| WHO/Lauren methodology | PASS | Explicitly excluded. |
| Detailed gastrectomy | PASS | Explicitly excluded. |
| Lymphadenectomy technique | PASS | Explicitly excluded. |
| Systemic-treatment algorithms | PASS | Explicitly excluded. |
| Detailed surveillance | PASS | Explicitly excluded. |
| Individualized treatment | PASS | Explicitly excluded. |
| Individualized prognosis | PASS | Explicitly excluded. |

---

# 4. Layer 2 — Clinical QA

## 4.1 Evidence Grounding

| Criterion | Result | QA Note |
|---|---|---|
| Source-first workflow | PASS | Project Source Files were searched before production. |
| Direct gastric-cancer guideline used | PASS | NCCN v2.2026 used as primary disease-specific source. |
| Regional guidance used | PASS | Vietnamese gastric-cancer guideline incorporated. |
| Patient-facing source used | PASS | ACS materials used for patient-facing explanation. |
| Unsupported clinical claims avoided | PASS | Claims are tied to the identified project sources. |
| Source gaps explicitly acknowledged | PASS | Technical ESD gaps are stated rather than filled silently. |

---

## 4.2 Indication Safety

| Criterion | Result | QA Note |
|---|---|---|
| No universal size-only rule | PASS | Size is described as one component of selection. |
| No universal stage-only rule | PASS | Early stage is not treated as automatic ESD eligibility. |
| Expanded indications qualified | PASS | Presented as selected contexts, not automatic cure. |
| Poorly differentiated lesions qualified | PASS | Selected expanded indication only; no blanket recommendation. |
| Ulcerated lesions qualified | PASS | Selected expanded context preserved. |
| Superficial versus deep invasion distinguished | PASS | Critical distinction preserved. |
| Nodal-risk rationale included | PASS | Central safety principle. |
| LVI incorporated | PASS | Curative assessment appropriately qualified. |
| Margins incorporated | PASS | Curative/non-curative logic preserved. |

---

## 4.3 Curative Assessment Safety

| Criterion | Result | QA Note |
|---|---|---|
| Technical success ≠ cure | PASS | Explicitly taught. |
| Pathology required | PASS | Explicit. |
| Depth relevant | PASS | Explicit. |
| LVI relevant | PASS | Explicit. |
| Margins relevant | PASS | Explicit. |
| Non-curative pathway acknowledged | PASS | Additional treatment may be needed. |
| Surgery not presented as automatic | PASS | Framed as context-dependent downstream management. |

---

## 4.4 ESD versus EMR Safety

| Criterion | Result | QA Note |
|---|---|---|
| ESD not described as universally superior | PASS | Greater capability balanced against complexity/risk. |
| EMR ownership preserved | PASS | Detailed EMR content delegated. |
| En-bloc distinction accurate | PASS | ESD greater capability described. |
| Technical complexity acknowledged | PASS | Explicit. |
| Bleeding/perforation risk acknowledged | PASS | Explicit. |

---

## 4.5 ESD versus Surgery Safety

| Criterion | Result | QA Note |
|---|---|---|
| Stomach-preservation value explained | PASS | Included. |
| Lymph-node limitation explained | PASS | ESD does not perform nodal dissection. |
| Surgery retained for higher-risk disease | PASS | Strategic downstream pathway. |
| Detailed surgery excluded | PASS | Correct boundary. |

---

## 4.6 No Unsafe Advice

| Item | Result | QA Note |
|---|---|---|
| No individualized ESD eligibility | PASS | Package does not diagnose suitability. |
| No treatment-switch instruction | PASS | None. |
| No surgery avoidance promise | PASS | Explicitly qualified. |
| No individualized prognosis | PASS | None. |
| No procedural self-instruction | PASS | Technical manual excluded. |
| No complication self-management | PASS | Detailed management excluded. |
| Encourages clinician discussion | PASS | Patient questions included. |

---

# 5. Layer 3 — Educational QA

## 5.1 Plain-Language Standard

| Criterion | Result | QA Note |
|---|---|---|
| Plain language | PASS | Technical terms are introduced with explanations. |
| Patient-friendly tone | PASS | Neutral, explanatory wording used. |
| One main concept per block | PASS | Knowledge organized into discrete blocks. |
| Short readable paragraphs | PASS | Long technical narratives avoided where possible. |
| Medical terminology explained | PASS | ESD, LVI, en-bloc, margins, submucosal concepts explained. |
| No sensational language | PASS | None. |
| No unsupported certainty | PASS | Context-dependent claims qualified. |

---

## 5.2 Learning Progression

| Criterion | Result | QA Note |
|---|---|---|
| Definition before indications | PASS | Logical sequence. |
| Modality comparison | PASS | EMR comparison follows ESD fundamentals. |
| Selection before pathology | PASS | Treatment logic precedes post-treatment assessment. |
| Curative assessment explained | PASS | Central pathway. |
| Downstream treatment explained | PASS | Non-curative pathway included. |
| Patient questions included | PASS | Practical endpoint. |
| Misconceptions included | PASS | Dedicated section. |

---

## 5.3 Common Misconceptions

The package explicitly addresses:

- ESD as biopsy.
- ESD as deeper EMR.
- Deep invasion misconception.
- “ESD is always better.”
- Technical removal equals cure.
- Negative margin alone equals cure.
- Size-only eligibility.
- Ulceration always excludes ESD.
- Poor differentiation always excludes ESD.
- Ignoring lymph nodes.
- ESD as a simple procedure.
- Center expertise.
- Avoiding surgery.
- No follow-up after ESD.

**Result: PASS**

---

# 6. Layer 4 — Governance QA

## 6.1 Gold Specification Compliance

| Criterion | Result | QA Note |
|---|---|---|
| Four-artifact model | PASS | CKO/KP/EP/QA all present. |
| CKO structure | PASS | Gold structure maintained. |
| KP structure | PASS | Gold structure maintained. |
| EP structure | PASS | Gold evidence sections and traceability maintained. |
| QA structure | PASS | Four-layer QA maintained. |
| Knowledge Graph | PASS | Prerequisite/related/downstream relationships included. |
| Versioning | PASS | v1.0.0. |
| Patient-facing style | PASS | Preserved. |
| Evidence traceability | PASS | Source-level mapping included. |
| Boundary ownership | PASS | Core/Supporting/Excluded/Delegated structure maintained. |

---

## 6.2 Absolute Gold Depth Review

### Gold Rule

The project governance establishes that Gold Reference Packages define the **minimum acceptable production depth** and that future packages must not be compacted, shortened, summarized, or reduced in:

- reasoning;
- evidence detail;
- QA detail;
- Knowledge Graph detail;
- patient-facing explanation;
- structural completeness.

### PP-0195 Assessment

| Dimension | Result |
|---|---|
| Structural completeness | PASS |
| Clinical reasoning depth | PASS |
| Evidence depth | PASS |
| Patient-facing depth | PASS |
| Knowledge Graph depth | PASS |
| QA depth | PASS |
| Boundary depth | PASS |
| Scope documentation depth | PASS |
| Evidence-gap documentation | PASS |
| Future-update documentation | PASS |

**Gold-depth conclusion: PASS**

---

# 7. Knowledge Graph QA

## Prerequisites

| Relationship | Result |
|---|---|
| Early gastric cancer | PASS |
| Endoscopic diagnosis | PASS |
| Biopsy | PASS |
| Histopathology | PASS |
| Endoscopic resection strategy | PASS |
| EMR context | PASS |

## Related

| Relationship | Result |
|---|---|
| Diagnostic endoscopy | PASS |
| Biopsy | PASS |
| Histopathology | PASS |
| EUS/staging | PASS |
| EMR | PASS |
| Surgery | PASS |

## Downstream

| Relationship | Result |
|---|---|
| Curative assessment | PASS |
| Surveillance | PASS |
| Additional surgery | PASS |
| Additional oncologic treatment | PASS |

**Knowledge Graph Status: PASS**

---

# 8. Adjacent Population Package Overlap QA

## Boundary With EMR

### EMR owns

- EMR-specific modality.
- Mucosal resection.
- EMR-specific selection.
- EMR-specific limitations.
- EMR-specific pathology interface.

### ESD owns

- Submucosal dissection.
- Greater en-bloc/resection capability.
- Classic/expanded ESD indications.
- ESD-specific risk/complexity.
- ESD-specific curative assessment.
- ESD-specific comparison with EMR and surgery.

**Overlap risk: LOW — PASS**

---

## Boundary With Endoscopic Resection Umbrella

Umbrella package owns:

- why endoscopic resection is considered.

PP-0195 owns:

- why and when ESD is the selected modality.

**Overlap risk: LOW — PASS**

---

## Boundary With Histopathologic Classification

Pathology package owns:

- detailed histopathology.

PP-0195 owns:

- why pathology findings determine curative adequacy after ESD.

**Overlap risk: LOW — PASS**

---

## Boundary With EUS/Staging

Staging packages own:

- detailed EUS/staging methodology.

PP-0195 owns:

- why pre-treatment staging matters for ESD.

**Overlap risk: LOW — PASS**

---

## Boundary With Surgery

Surgical packages own:

- gastrectomy;
- lymphadenectomy;
- surgical technique.

PP-0195 owns:

- why non-curative ESD may lead to surgery.

**Overlap risk: LOW — PASS**

---

# 9. Source Traceability QA

| Source | Used | Role | Result |
|---|---|---|---|
| NCCN Gastric Cancer v2.2026 | Yes | Primary guideline | PASS |
| Vietnamese gastric-cancer guideline | Yes | Regional guideline | PASS |
| ACS Stomach Cancer | Yes | Patient-facing explanation | PASS |
| ACS Immunotherapy for Stomach Cancer | Yes | Early-stage treatment context | PASS |
| Gold Discussion template | Yes | Structure/depth | PASS |
| Gold specification | Yes | Artifact standard | PASS |
| CORE_WORKING_RULES | Yes | Workflow/governance | PASS |

---

# 10. Evidence Gap QA

The package explicitly acknowledges that the Source Materials do not adequately support a technical ESD manual.

This is a strength rather than a defect because:

- the Source-First rule prohibits silent filling of gaps;
- detailed procedural technique is outside the locked patient-facing scope;
- a technical package can be created separately if the project later requires it.

**Evidence Gap Handling: PASS**

---

# 11. Patient-Facing Safety Review

| Safety Requirement | Result |
|---|---|
| Explain ESD in accessible terms | PASS |
| Explain why it may be offered | PASS |
| Explain selection factors | PASS |
| Explain limits | PASS |
| Explain potential complications | PASS |
| Explain pathology role | PASS |
| Explain possibility of additional surgery | PASS |
| Avoid individualized recommendation | PASS |
| Encourage clinician discussion | PASS |
| Avoid false reassurance | PASS |
| Avoid treatment guarantees | PASS |

---

# 12. Repository QA

## Required Package Structure

```text
PP-0195_ESD_Endoscopic_Submucosal_Dissection_GOLD_v1.0.0/
├── 01_CKO.md
├── 02_KNOWLEDGE_PASSPORT.md
├── 03_PRIMARY_EVIDENCE_PACKAGE.md
└── 04_QA_REPORT.md
```

### Repository Criteria

| Criterion | Result |
|---|---|
| Correct PP number | PASS |
| Full title included in package name | PASS |
| Four standard artifact names | PASS |
| Markdown format | PASS |
| Semantic versioning | PASS |
| ZIP-ready | PASS |
| No unnecessary files | PASS |

---

# 13. Final Boundary QA

## Core

ESD as a specialized endoscopic treatment modality for selected early gastric cancer, including selection, classic and expanded indications, submucosal/en-bloc resection, depth, histology, ulceration, LVI, margins, nodal-risk rationale, pathology/curative assessment, ESD-versus-EMR, ESD-versus-surgery strategy, risks, expertise, and downstream implications.

## Supporting

Pre-treatment staging/EUS interface, specimen diagnostic value, East Asian evidence context, study-level outcomes, stomach preservation, surveillance rationale, and patient-facing questions.

## Explicitly Excluded

Detailed ESD technique, device/electrosurgical mechanics, detailed complication management, detailed EUS/staging methodology, detailed pathology methodology, detailed surgery/lymphadenectomy, systemic-treatment algorithms, detailed surveillance/recurrence algorithms, individualized treatment, and individualized prognosis.

## Delegated-to PP

EMR → PP-0194; endoscopic diagnosis → PP-0176; biopsy → PP-0177; histopathology → PP-0178; EUS/staging → dedicated packages; surgery/gastrectomy → surgical packages; surveillance → dedicated follow-up packages.

**Boundary QA: PASS**

---

# 14. Final Clinical QA Decision

## Overall Assessment

The PP-0195 Gold package:

- implements the approved/locked Decision Batch;
- preserves the ESD-specific clinical identity;
- is grounded in the project Source Materials;
- distinguishes classic and expanded indications;
- preserves the critical distinction between technical removal and curative resection;
- correctly places pathology downstream of ESD;
- preserves the boundary with EMR;
- preserves the boundary with surgery;
- does not silently fill evidence gaps;
- avoids individualized medical advice;
- maintains patient-facing usability;
- maintains the required Gold artifact architecture.

---

# 15. QA Decision

| QA Layer | Result |
|---|---|
| Layer 1 — Content QA | PASS |
| Layer 2 — Clinical QA | PASS |
| Layer 3 — Educational QA | PASS |
| Layer 4 — Governance QA | PASS |
| Source Traceability | PASS |
| Knowledge Graph | PASS |
| Boundary | PASS |
| Gold Depth | PASS |
| Repository Readiness | PASS |

# FINAL QA STATUS

## **PASS — GOLD — READY FOR INTEGRATION**


---

# 16. Cross-Artifact Consistency QA

## Identity Consistency

| Check | Result |
|---|---|
| PP ID = PP-0195 in all artifacts | PASS |
| Title = ESD / Endoscopic Submucosal Dissection | PASS |
| Version = 1.0.0 | PASS |
| Status = GOLD | PASS |
| Scope centered on ESD | PASS |

## Clinical Terminology Consistency

| Term | Result |
|---|---|
| ESD = endoscopic submucosal dissection | PASS |
| EMR = endoscopic mucosal resection | PASS |
| LVI = lymphovascular invasion | PASS |
| ER = endoscopic resection | PASS |
| EUS = endoscopic ultrasound | PASS |
| En-bloc resection | PASS |
| Curative/non-curative | PASS |

## Scope Consistency

| Topic | CKO | KP | EP | QA | Result |
|---|---|---|---|---|---|
| ESD definition | Yes | Yes | Yes | Yes | PASS |
| Indications | Yes | Yes | Yes | Yes | PASS |
| Expanded indications | Yes | Yes | Yes | Yes | PASS |
| Pathology | Yes | Yes | Yes | Yes | PASS |
| Curative assessment | Yes | Yes | Yes | Yes | PASS |
| ESD vs EMR | Yes | Yes | Yes | Yes | PASS |
| Surgery interface | Yes | Yes | Yes | Yes | PASS |
| Risks | Yes | Yes | Yes | Yes | PASS |
| Expertise | Yes | Yes | Yes | Yes | PASS |
| Surveillance | Yes | Yes | Yes | Yes | PASS |
| Technical procedure | Excluded | Excluded | Excluded | Excluded | PASS |

---

# 17. Clinical Reasoning QA

## Reasoning Chain

The package preserves the following causal chain:

**Early gastric cancer**

↓

**Assess depth / histology / size / ulceration / nodal risk**

↓

**Determine whether endoscopic treatment is oncologically reasonable**

↓

**Select ESD when its greater resection/en-bloc capability is appropriate**

↓

**Obtain complete specimen**

↓

**Assess pathology**

↓

**Determine curative versus non-curative status**

↓

**Surveillance OR additional treatment**

### Result

**PASS**

The chain is clinically coherent and does not skip directly from “early cancer” to “ESD.”

---

# 18. Claim Calibration QA

| Potential Overclaim | Corrective Handling | Result |
|---|---|---|
| “ESD is always best” | Replaced with guideline-specific preference + context | PASS |
| “ESD cures all early cancers” | Replaced with selected/curative criteria language | PASS |
| “<2 cm automatically qualifies” | Size treated as one selection factor | PASS |
| “Ulceration excludes ESD” | Expanded indications preserved | PASS |
| “Poor differentiation excludes ESD” | Selected expanded indication preserved | PASS |
| “Deeper ESD treats deep invasion” | Deep invasion identified as potential non-curative feature | PASS |
| “Negative margin alone proves cure” | Multi-factor curative assessment | PASS |
| “ESD means no surgery” | Additional-surgery pathway retained | PASS |
| “ESD is low-risk” | Bleeding/perforation and complexity included | PASS |
| “Any center can perform ESD” | High-volume expertise requirement included | PASS |

---

# 19. Source-First Compliance Audit

## Required Source-First Actions

| Requirement | Result |
|---|---|
| Search exact PP identity | PASS |
| Search clinical source materials | PASS |
| Search adjacent package context | PASS |
| Search Discussion template | PASS |
| Search Gold specification | PASS |
| Search governance rules | PASS |
| Identify evidence gaps | PASS |
| Avoid silent general-knowledge substitution | PASS |

### Audit Conclusion

The package was built from the project Source Files and the approved Gold governance references.

**Source-First Audit: PASS**

---

# 20. User-Controlled Sequence Audit

| Rule | Result |
|---|---|
| Execute only explicitly requested PP | PASS |
| No automatic next-PP selection | PASS |
| No sequence inferred from number | PASS |
| No sequence inferred from Knowledge Graph | PASS |
| Stop after completion | PASS |

**Sequence Governance: PASS**

---

# 21. Gold Depth Audit

## Required Gold Dimensions

### Discussion/Reasoning

- Full decision rationale preserved in the preceding approved Decision Batch.
- No compact replacement of clinical reasoning in artifacts.

### CKO

- Metadata.
- Objectives.
- Scope.
- Knowledge blocks.
- Patient explanation.
- Clinical importance.
- Key concepts.
- Misconceptions.
- Key messages.
- Knowledge Graph.
- Revision history.

**Result: PASS**

### Knowledge Passport

- Identity.
- Classification.
- Patient journey.
- Runtime use.
- Retrieval terms.
- Clinical scope.
- Evidence classification.
- Governance.
- Versioning.
- Clinical reasoning notes.
- Runtime guardrails.
- Update sensitivity.

**Result: PASS**

### Primary Evidence Package

- Clinical question.
- Educational intent.
- Scope.
- Sources.
- Hierarchy.
- Evidence matrix.
- Evidence notes.
- Claims summary.
- Consistency review.
- Gaps.
- Update triggers.
- Traceability.
- Boundary verification.
- Evidence decision.

**Result: PASS**

### QA

- Four-layer QA.
- Content review.
- Clinical safety.
- Educational review.
- Governance.
- Cross-artifact consistency.
- Reasoning calibration.
- Source-first audit.
- Boundary audit.
- Repository audit.
- Final decision.

**Result: PASS**

---

# 22. Patient-Facing Risk Communication Audit

The package:

- does not promise cure;
- does not promise stomach preservation;
- does not promise avoidance of surgery;
- does not minimize ESD complexity;
- does not provide procedural instructions;
- does not provide complication-management instructions;
- explains why pathology matters;
- explains why additional treatment may be needed;
- directs individual decisions to the care team.

**Patient Safety Communication: PASS**

---

# 23. Boundary Integrity Audit

## Core Ownership

ESD modality-specific clinical education.

**PASS**

## Supporting Ownership

Context needed to understand ESD without absorbing adjacent packages.

**PASS**

## Explicit Exclusion

Technical, pathology-methodology, surgical, systemic, surveillance-algorithmic and individualized content excluded.

**PASS**

## Delegation

Adjacent ownership is explicitly named.

**PASS**

---

# 24. Final Governance Statement

The PP-0195 package is compliant with the project rule that:

- Population Packages are governed Knowledge Products.
- Gold references define the minimum depth.
- Four artifacts are mandatory.
- Source-First is mandatory.
- User-controlled PP sequence is authoritative.
- Locked decisions move directly to artifact production.
- Boundaries must be explicit.
- Knowledge Graph links must be maintained.
- Clinical claims must remain source-grounded.
- QA must be substantive.

**Governance compliance: PASS**

---

# 25. Final QA Decision

| Domain | Decision |
|---|---|
| Content | PASS |
| Clinical | PASS |
| Educational | PASS |
| Governance | PASS |
| Source Traceability | PASS |
| Boundary | PASS |
| Knowledge Graph | PASS |
| Gold Depth | PASS |
| Repository Readiness | PASS |

## Final Status

# **PASS — GOLD — READY FOR INTEGRATION**
